December 23, 2021
Meiji Seika Pharma said on December 22 that it will initiate a PIb/II clinical trial in Japan to obtain an additional indication for the anti-malignant tumor agent Hiyasta (tucidinostat). The trial is expected to begin next March. The trial will...read more